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Abstract 
Background: Smart drug use is increasing but we have little insight into their use. We hypothesized that use 
is predicted by attitudes and various factors including incremental morality and entity intelligence beliefs 
would be associated with positive attitudes, whilst perception of unfairness would be associated with negative 
attitudes.  
Methods: UK undergraduates completed an online survey to establish attitudes towards smart drugs, previous 
use and likely future use as well as measures of several factors hypothesized to predict attitudes.  
Results: Attitudes were found to predict previous and likely future use. Attitudes were more positive in those 
who believed that smart drugs were harmless and those who felt they knew enough to use them safely. By 
contrast, perceived unfairness was associated with negative attitudes.  
Conclusions: Interventions to reduce smart drug use should focus on attitudinal beliefs around potential harm 
and safety, as well as emphasizing the debate around unfairness.  
 
Keywords 
Cognitive enhancement; implicit theories; drug safety 
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Introduction 
 
Smart drugs, also known as cognitive enhancers, are prescription drugs taken by individuals, either without a 
prescription or at a dose exceeding that which is prescribed, with the intention of improving cognitive 
functions such as concentration, vigilance or memory [1]. In some cases, the drugs may also result in changes 
to mood (i.e. emotional enhancement) but this is not typically the aim of taking smart drugs [2] Commonly 
used smart drugs include methylphenidate (Ritalin, Concerta), amphetamine (Adderall), and modafinil 
(Provigil) but other classes of drug are also discussed in this context, including acetylcholine esterase 
inhibitors and beta-blocker [3, 4]. The main cognitive enhancers used were originally designed to treat a range 
of disorders including Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy [5], by targeting 
various deficits in cognitive functioning such as attentional biases, aberrant learning, and absence of top-down 
cognitive control [3]. However, they are increasingly being used by healthy individuals, though questions 
remain around their ability to enhance cognition within non-clinical populations [5-7]. One population for 
whom smart drug use is thought to be particularly prevalent is university students, who seek to enhance 
cognitive functioning to improve academic performance [5, 8-10].  Smart drug prevalence estimates in 
students range from 5-35% in the US [10], 1-16% in Europe [11-13], and 0.02-9% in the UK [14, 15].  
 
In addition to debate around the effectiveness of smart drugs in healthy populations, the use of drugs to gain 
an academic advantage has sparked a bioethical debate, in which smart drugs have been framed as analogous 
to doping in sport. Focus groups with university students, their parents and health care professionals identified 
one of most contentious issues surrounding smart drug use was the potential injustices and inequalities that 
could arise from their use [16]. Specifically, they found that views on equality of opportunity, that is whether 
everyone has equal access to forms of enhancement and therefore the benefits they bring, are critical in 
understanding how people perceive smart drugs. By contrast, honesty and authenticity of performance, appear 
less important [16, 17].  
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Safety concerns have also been raised [18]. Evidence relating to the health and safety impact of smart drugs 
is lacking because most studies investigating drug effects do so in the context of them being used as 
prescription medication in clinical populations, which may mean findings do not apply to healthy individuals 
using the drugs as smart drugs. Yet, the limited research available suggests that whilst modafinil has no serious 
side effects in the short term, the psychostimulants methylphenidate and amphetamine have been linked with 
short-term side-effects such as cerebrovascular complications, anxiety and decreased connectedness [7]. The  
long-term effects (>1 year) are largely unknown owing to a lack of longitudinal studies in healthy populations 
[19]. However, work in ADHD populations, including several randomised control trials, indicates that the 
psychostimulants are associated with relatively mild side effects such as a dry mouth [20, 21]and reduced 
appetite but also more serious effects of increased in heart rate and blood pressure [21-24]. Comparative 
studies have found, perhaps unsurprisingly, that users are less concerned about the safety of smart drugs than 
non-users [6, 25], and perceptions of the severity of possible health risks have been inversely associated with 
willingness to use smart drugs [26-32].   
 
Given the possibility that these drugs are not effective in healthy individuals, concerns about fairness, and 
potential health risks, it is important to better understand determinants of smart drug use. Alongside work 
showing lesser safety concerns among users [6], studies have found that higher levels of study-related stress 
are associated with increased cognitive enhancement through both lifestyle drugs (e.g. caffeine) and some 
prescription drugs [3, 15, 33, 34]; indeed, prevalence rates are doubled in highly competitive universities, 
where stress may be greater [35]. It has been argued that, as smart drug use becomes more prevalent, other 
students may feel greater pressure to use smart drugs, to remain competitive against smart drug users [19]. 
Empirical evidence, which has focused on two types of norms – i.e., perceptions of others’ attitudes towards 
smart drug use (injunctive norms), and perceptions of others’ smart drug use (descriptive norms) [36] – has, 
however, been mixed. While awareness of others using smart drugs (i.e. descriptive norms) has been found to 
increase use [15], perceived encouragement from others to use smart drugs (i.e. injunctive norms) has been 
found to have no impact on willingness to take smart drugs [28]. A study of 65 Canadians suggested that users 
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viewed decisions to take cognitive enhancing substances as self-determined, rather than the result of coercion 
from others, though it remains possible that self-authored decisions are nonetheless informed by perceptions 
of the social environment [17].  
 
One area that has received little attention in the literature is whether there is any association between smart 
drug use and implicit beliefs about personal attributes; i.e., beliefs held, often without awareness, about the 
very nature of one’s own attributes. Dweck et al. [37] propose that people hold one of two implicit belief 
theories regarding the flexibility of personal attributes, and these theories impact on processing of social 
information and human actions. With regards to intelligence, for example, an individual may subscribe to an 
‘entity theory’, viewing intelligence as fixed, or an ‘incremental theory’, viewing intelligence as modifiable. 
Implicit intelligence beliefs tend to be important in education in general, determining an individual’s goals, 
responses to difficulty and educational attainment [37, 38]. Entity intelligence theorists tend to pursue 
performance goals [39], placing emphasis on the winning outcome and focusing on tasks that verify their 
intellectual ability, whereas incremental intelligence theorists tend to pursue mastery goals focusing on 
learning new concepts and improving their competence [40]. While not yet investigated within the smart drug 
domain, research has shown that those who hold entity beliefs are more likely to cheat on exams after initial 
failure in order to maintain the appearance of high achievement [41]. It is therefore plausible that entity 
theorists may view smart drugs more positively than incremental theorists. Implicit theories have been 
identified for morality [37] – that is, beliefs in whether morality is fixed or can shift across settings – but, 
despite the bioethical debate around smart drugs, the role of implicit morality beliefs in shaping smart drug 
use has not been investigated. Given widely-held views that smart drugs are unfair [16, 17], we speculate that 
those who hold positive attitudes towards smart drugs may be more likely to hold incremental morality beliefs, 
believing that, in some settings, engaging in ‘unfair’ behaviour is not indicative of a general lack of morality.  
 
This study sought to model determinants of beliefs about smart drugs and related behavioural tendencies 
among UK-based undergraduate students. Using a cross-sectional survey design, we measured global attitude 
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towards smart drugs, previous smart drug use and behavioural expectation i.e., the likelihood that the 
participant would use smart drugs in the future [42]. A wealth of research demonstrates that attitudinal beliefs 
typically correspond with intentions and behaviour [43, 44]. Thus, we hypothesized that: 
 
1. Positive attitudes towards smart drugs would be associated with higher levels of actual past use, and 
greater expected future use. 
 
Support for this hypothesis would justify modelling smart drug attitudes as an outcome of interest in 
subsequent analyses. Measures were thus taken of potential determinants of smart drug attitudes: study stress, 
awareness and availability of smart drugs, perceptions of safety and fairness, and implicit morality and 
intelligence beliefs. We hypothesized that: 
2. Greater study stress, awareness of others’ use, availability, beliefs that smart drugs are safe, and 
endorsement of incremental morality and entity intelligence theories, will be associated with more 
positive attitudes towards smart drugs.  
3. Beliefs that taking smart drugs is unfair will be associated with more negative attitudes towards smart 
drugs. 
 
Materials and Methods 
 
Sampling period 
The study ran from November until March (i.e. for a four-month period). This period includes an examination 
period and typical end of term deadlines at the host institution and this academic year is typical of many UK 
universities. 
 
Participants and procedure 
Eligible participants – i.e., full-time undergraduates at a UK university, aged 18 years or over – completed an 
online survey. The study was advertised via email circulars to students at the host institution, King’s College 
London, a research-intensive Russell Group university in the UK. It was additionally advertised on social 
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media (Facebook, LinkedIn, Twitter), student websites (e.g. www.studentroom.co.uk), and on posters 
displayed at multiple London universities. Study adverts featured a URL or QR code linking to the study 
information and a consent form. Consenting participants were granted access to the online questionnaire, 
which took approximately 30 minutes to complete. Those who completed the questionnaire were offered entry 
into a £100 Amazon.co.uk voucher prize draw. All procedures were approved by the King’s College London 
Psychiatry, Nursing & Midwifery Research Ethics Subcommittee (HR15/162824). 
 
Of 612 participants who started the questionnaire, 191 failed to complete and one did not meet the age 
criterion, yielding a final sample of 420 participants (298 female [71%], 122 male [29%])). Age ranged from 
18 to 58 years (mean = 21.58 years, SD = 3.83) with most participants (92.2%) being aged between 18 and 25 
years of age and, therefore, of typical university student age. Most participants have previously only completed 
school level qualifications as would be expected for those studying an undergraduate degree (94.5%) however, 
a small proportion had previously completed postgraduate qualifications (certificate, diploma or masters, 
4.5%) or a professional qualification (1%) suggesting a minority may be returning to higher education.  An a 
priori power analysis suggested that a minimum sample size of n = 103 was required to achieve power at 0.80 
using a multiple regression with 7 predictor variables and a small overall predicted effect size (f=0.15). 
 
Measures 
All measures were self-reported. Unless otherwise specified, multi-item measures were combined into a global 
scale mean score. Reliability coefficients (Cronbach’s alpha) are reported for all multi-item scales designed 
to tap the same latent construct. 
 
Global attitudes towards smart drugs were measured via a single item: ‘Please indicate your attitude to using 
smart drugs’ (1=extremely negative, 5=extremely positive).  
 
Previous smart drug use. Participants indicated whether, since the beginning of their university studies, they 
had ever taken any of the following drugs with the intent to provide cognitive enhancement (yes/no): 
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methylphenidate, amphetamine, modafinil, beta-blockers or rivastigmine. These drugs were all chosen based 
on frequent citation in the literature on smart drug use [45-47] and recent work showing similar use of the 
different types of drugs in student populations [4]. Those reporting use (i.e. ‘yes’) were asked to indicate 
which of the drugs listed they had used, and the frequency with which they took them 
(seldom/sometimes/regularly/often). Finally, those reporting use were asked to rank the importance of four 
potential reasons for taking smart drugs: to look ‘smart’; to achieve a study goal; to support learning, or ‘other’ 
(1 = most important, 4 = least important). Those reporting that they had not used smart drugs were not asked 
further questions about this decision. In addition, no question about other drug use (prescription or otherwise) 
were asked of any participants. 
 
Behavioural expectation. Given the cross-sectional design, future use of smart drugs could not be assessed. 
Therefore, we asked students to estimate the likelihood that they would consider taking a smart drug in the 
next 12 months (1=extremely unlikely, 5=extremely likely).  
 
Study stress was measured using a ten-item Perceived Stress Scale [48], previously modified to relate to 
studying [3] (e.g. ‘In the last month, how often have you felt nervous and stressed about your studies?”; 
1=never, 5=very often; α = 0.89). 
 
Following Schelle et al [3], awareness and accessibility of smart drugs was measured using six items, each 
measuring different aspects of awareness and accessibility (e.g. “I am aware of students using smart drugs 
regularly”; 1= strongly disagree, 5= strongly agree).  Safety views were measured by two separate items [3], 
one measuring perceived safety and another knowledge of safety (“I think it is harmless to use smart drugs”, 
“I know enough about 'smart drugs' to safely use them”; 1= strongly disagree, 5= strongly agree). Perceived 
fairness was measured using a single item: “I think that smart drugs provide an unfair advantage for students 
compared to those that do not take them” (1= strongly disagree, 5= strongly agree; [3]). 
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Implicit intelligence beliefs were measured using the eight-item Theory of Intelligence Scale (e.g. ‘your 
intelligence is something about you that you can’t change very much’ [1 = strongly disagree, 6 = strongly 
agree]; α = 0.94) [37]. Implicit morality beliefs, i.e. whether a participant believed their moral character to be 
fixed or flexible, were measured using the three-item Implicit Theory of Morality Scale (e.g. ‘your moral 
character is something basic about you and you can’t change much’ [1=strongly disagree, 6=strongly agree]; 
α = 0.90) [37]. 
 
Data Analysis  
 
Data preparation 
Fairness (1 item), safety (2 items), and awareness and availability (6 items) measures are not part of a 
standardised scale. Scores on these items could feasibly co-vary, and so the nine items were subjected to an 
exploratory factor analysis, to identify whether these items could be reduced to a smaller number of latent 
factors, thus reducing overlap between items. Two factors were identified (i.e. eigenvalues > 1), on each of 
which component items showed loadings over 0.40. The first factor (eigenvalue = 3.75, 41.66% variance 
explained), which consisted of five items (‘I am aware of students using smart drugs regularly’, ‘I am aware 
of students using 'smart drugs' at particularly intense study times (e.g. deadlines and exams)’, ‘I have spoken 
about 'smart drugs' with other students’, ‘I have been offered 'smart drugs' by another student’, ‘'Smart drugs' 
are readily accessible on this campus.’), was labelled ‘Awareness and Availability’. The second factor 
(eigenvalue = 1.65, 18.36% variance explained) consisted of two items (‘I think it is harmless to use 'smart 
drugs'’, ‘'Smart drugs' should be freely accessible’) and was labelled ‘Perceived Harmlessness’. The two 
factors correlated at r = .221. These two factors, and two items which did not load on either factor, which were 
labelled ‘Perceived Safety Knowledge’ (‘I know enough about 'smart drugs' to safely use them’) and 
‘Unfairness’ (‘I think that 'smart drugs' provide an unfair advantage for students compared to those that do not 
take them’), were entered into analysis as discrete variables.   
 
Hypothesis testing 
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The relationship between attitudes and use (previous, and forecast future use; i.e. Hypothesis 1) was assessed 
using two univariate regression models, modelling previous use, and behavioural expectation respectively, in 
both of which attitude was entered as the sole predictor variable. Hypotheses 2 and 3 were tested using 
correlation and regression analyses. First, Pearson's correlations between each hypothesised predictor variable 
and attitude towards smart drugs identified significant correlates (p < .05), which were subsequently entered 
into a multiple regression model. To achieve the most parsimonious predictive model, backwards stepwise 
elimination was used, whereby redundant hypothesised predictors are systematically removed from the model, 
until further refinement is not possible without losses in predictive utility. All regression model assumptions 
were met [49]: no multicollinearity or singularity was observed among predictors at any stage within the 
backwards model, with all tolerance values were below 0.2 or 0.1, and all variance inflation factor scores 
approximating 1, and none above 10.  
 
Results 
 
Sample characteristics 
 
Of 420 participants, 17.1% (N=72; 43 male, 29 female) reported having used smart drugs previously. There 
was no difference between previous users (mean = 22.37 years, SD = 3.73) and non-users (mean = 21.43 
years, SD = 3.73) in terms of age (t(412) = 1.92, p = .055). There was, however, a difference in gender profile 
between users and non-users (χ2(1) = 5.32, p = .032) with males more likely to take smart drugs. Of users, 
58.3% (N=42) reported only having used modafinil, 11.1% (N=8) using only amphetamine, 9.7% (N=7) using 
only beta-blockers, and 8.3% (N=6) using only methylphenidate. Nine (13% of users) reported trying more 
than one smart drug. We analysed choice of drug in three categories (modafinil, psychostimulants and beta-
blockers) to see if there were any differences by age using a One-Way ANOVA. This revealed significant 
differences (F(2, 60) = 11.84, p < .001). Post-hoc Tukey tests revealed that those taking beta-blockers (mean 
= 28.89 years, SD = 11.05) were significantly older than those taking psychostimulants (mean = 21.44, SD = 
1.53, p < .001) or modafinil (mean = 21.50 years SD = 1.57, p < .001). The majority of the 72 users reported 
‘seldom’ use (56.9%, N=41), whilst 22.2% (N=16) reportedly used them ‘sometimes’ and 16.7% (N=12) 
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reported regular use. Three did not specify. There was no significant correlation between age and frequency 
of use (r = .087, p = .471). Due to the small sample sizes for some drugs and frequency of uses, it was not 
possible to conduct an analysis by gender for either of these. The most commonly endorsed reason for using 
smart drugs was ‘Other’, with 47% (N=34) of participants ranking this as most important and citing a range 
of reasons including to enhance focus and concentration, combat tiredness, and reduce stress. ‘To support 
learning’ was the second highest scoring reason, followed by ‘to look smart’. The least commonly-endorsed 
reason was ‘to achieve a study goal’. Eight users reported using them for multiple purposes, including but not 
limited to smart drug use. The most common additional reason for use, i.e. on top of using smart drugs for 
cognitive enhancement, was for recreational use.  
The relationship between attitudes, previous use and behavioural expectation 
Participants with more positive attitudes towards smart drugs were more likely to have taken them previously 
(r = .47, p < .001), and attitude predicted 22.4% of variance in previous smart drug use, (Model F (1, 418) = 
120.62, p < .001). Similarly, those with positive attitudes believed they were more likely to use them in future 
(r = .69, p< .001), with attitude predicting 48.1% of variance in behavioural expectation (Model F (1, 148) = 
387.33, p < .001;  = .69, p < .001). Hypothesis 1 was thus supported, and the role of positive attitude in 
predicting previous or likely future use justified the emphasis of our subsequent analyses on attitudes as an 
outcome of interest.  
 
Factors predicting attitudes to smart drugs 
As might be expected from the analysis of previous users and non-users there was no significant relationship 
between age and attitude to smart drugs (r = -.029, p < .547). There was, however, a gender difference with 
males were more likely to exhibit more positive attitudes (mean = 2.82, SD = 1.16) than females (mean = 
2.32, SD = 0.95; t(418) = 4.62, p < .001).  
 
‘Awareness and Availability’ (r = .30, p < .001) and ‘Perceived Harmlessness’ (r = .71, p < .001) both 
correlated with attitudes, such that those who were more aware of smart drugs and thought them readily 
available or who perceived them as harmless were more likely to hold positive attitudes towards the drugs 
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(see Table 1). ‘Perceived Safety Knowledge’ was also positively associated with attitudes, with those who 
more strongly felt that they knew enough about smart drugs to use them safely showing more positive attitudes 
(r = .52, p < .001). Finally, attitude was negatively associated with ‘Unfairness’ (r = -.40, p < .001), with those 
more strongly believing that smart drugs offered an unfair advantage holding more negative attitudes towards 
them. There was no correlation between stress and attitude to smart drugs (r=.028, p=.29). Neither intelligence 
(r=-.003, p = .50) nor morality beliefs (r=.023, p = .33) were associated with smart drug attitudes. Hypothesis 
2 thus received mixed support, and Hypothesis 3 was supported. 
 
At the first step, a model comprising Awareness and Availability, Perceived Harmlessness, Perceived Safety 
Knowledge, and Unfairness explained 59.2% of variance in attitude towards smart drugs (R2 = .592, Model F 
(4, 417) = 149.77, p < .001) Removing Awareness and Availability at the second step did not improve the 
predictive power of the model but created a more parsimonious model, which explained 58.9% of variance in 
attitudes R2 = .589, F change = 3.301, p = .07; Model F (3, 417) = 197.496, p < .001). Within this model, 
Perceived Harmlessness (B = .62, p < .001) and Perceived Safety Knowledge (B = .17, p < .001) were positive 
predictors, while Unfairness had a negative effect on smart drug attitudes (B = -.18, p < .001). Given the 
association between gender and attitudes this analysis was repeated with gender included. However, the final 
model was unaffected and therefore the analysis not reported here.  
 
Discussion  
 
Positive attitudes towards smart drugs were found to predict rates of previous use, and forecasted future use 
in line with the theory of planned behaviour [43]. Following on from this we found that participants who 
believed smart drugs to be harmless, and those who felt they knew enough to use them safely, tended to have 
more positive attitudes, while those who felt that smart drug use was unfair had more negative attitudes. These 
findings suggest that smart drug use might be reduced through raising awareness of the absence of evidence 
regarding their safety and emphasising ethical arguments around the fairness of using smart drugs to 
potentially enhance cognitive performance. 
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Beliefs that smart drugs pose little risk to safety, and greater confidence in such beliefs, were linked to positive 
attitudes towards using smart drugs. Views about the harmlessness of smart drugs were associated with views 
towards their accessibility, which we interpret to indicate that those who perceive smart drugs to pose little 
harm consequently believe that they should be readily available. Previous studies have suggested that users 
consider the safety of smart drugs by comparison with street drugs, and the fact that they are regularly 
prescribed by doctors for various conditions, can be used as a means of downplaying potential health risks 
[50]. A lower perceived risk of harm could be a reason for a more positive attitude towards using smart drugs. 
It is unclear whether those who believe they have adequate knowledge of smart drugs to use them safely are 
simply unaware of possible safety risks, or recognise the potentially negative side effects but believe them to 
be outweighed by cognitive enhancement benefits [51]. Alternatively, people with more positive attitudes may 
consequently downplay safety concerns [11]. The same bidirectional relationship may underpin the 
relationship we observed between unfairness and smart drug attitudes. Non-users have been argued to be more 
ethically minded than users [15], such that perceptions of unfairness may lead to negative attitudes, though 
conversely, people seeking to rationalise their negative attitudes may subsequently portray smart drugs as 
unfair. The true causal direction of the relationships between beliefs and global attitudes among our sample 
cannot be fully established due to our cross-sectional design. A measure of awareness and availability of smart 
drugs, as derived from factor analysis, correlated with attitude towards smart drugs, which corresponds with 
previous findings that awareness and availability of smart drugs influences the decision of whether to take 
them [15]. Yet, this did not predict smart drug attitudes when controlling for perceptions of harmlessness, 
safety knowledge, and unfairness. Moderately strong positive correlations were observed between awareness 
and availability, and harmlessness and safety knowledge perceptions, suggesting that people who were aware 
of smart drug use and believed that they should be available also tended to view them as harmless, and were 
confident that their views were based on adequate knowledge of their safety. Awareness and availability 
beliefs may therefore represent a proxy for perceived harmlessness and safety knowledge, such that, when the 
three variables are mutually controlled, awareness and availability did not emerge as an independent predictor. 
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Interventions to reduce smart drug use may therefore be more effective if targeting perceptions of harm, and 
challenging users’ knowledge regarding safety, than targeting the availability beliefs that may follow from 
these perceptions. 
 
Surprisingly, given previous studies reporting a positive relationship between stress and smart drug use [3, 28, 
33, 34], study-related stress did not correlate with smart drug attitudes. There are several possible explanations 
for this. Firstly, the discrepancy may arise because previous studies have modelled actual use whereas we 
have modelled attitude. Whilst attitudes are hypothesized to predict behaviour and we have demonstrated they 
do so in this context, they are not the only factor to do so [43]. Therefore, it is plausible that stress does predict 
use but that this is not mediated by attitude. Secondly, the difference may arise because different smart drugs 
have different relationships with stress. In the current study, our previous use data showed that the majority 
of those in our cohort who did use smart drugs, chose to use modafinil. It may, therefore, be the drug that our 
cohort is most aware of irrespective of personal use, and therefore the most influential when determining their 
views of smart drugs. Previous work has shown that the strongest relationship between stress and cognitive 
enhancement is found with lifestyle drugs, such as caffeine, or specific prescription drugs, most commonly 
methylphenidate and beta-blockers are considered [3, 33, 34]. In the present study we did not consider lifestyle 
drugs and, although methylphenidate and beta-blockers were used, they were not the most prevalent indicating 
students from this cohort may more commonly consider modafinil when reflecting on smart drugs. Whilst 
psychostimulants have been shown to have some stress-relieving effects in healthy people [52], modafinil has 
been shown to trigger stress responses [53]. Therefore, it may be important to establish the relationship 
between stress and specific smart drugs, rather than assume the same relationship exists for them all. Another 
possible explanation of the lack of relationship between stress and attitude to smart drugs is the overall level 
of stress. One previous study, found that the only stress-related item they measured which significantly 
predicted drug use was whether students felt the demands of their study were overwhelming [54]. It is 
therefore possible, that any level of stress up until this point of feeling overwhelmed is not sufficient to impact 
on attitude to smart drugs. This explanation would seem unlikely to explain our lack of relationship because 
 14 
 
 
our measure of stress showed a range of 1-4.8 on a scale of 0-5, indicating that at least in some cases, individual 
rated themselves as very stressed.  
 
We found no evidence that intelligence beliefs were associated with attitudes towards smart drugs. Previous 
research has shown that people who believe that intelligence is a fixed entity i.e. not something they can 
change are more likely to cheat in situations that are thought to have the potential to reveal intelligence, such 
as exams, as they feel that this is the only way to overcome the constraints imposed by their intelligence [41]. 
Thus, we hypothesized that these individuals may also hold more positive attitudes towards smart drugs, which 
frequently spark debate around honesty and are deemed by some as analogous to doping in sports i.e. cheating. 
The lack of a relationship between intelligence beliefs and smart drug attitudes may have occurred for several 
reasons. Firstly, our data may not have had sufficient range to show any effects. This is unlikely because the 
scores were normally distributed around a mean of 3.68 on a scale of 1-6 with all scores represented, indicating 
this is unlikely to be the case. Secondly, the lack of relationship may indicate that students do not give much 
consideration to whether smart drugs are cheating. This is in line with previous research showing that honesty, 
and by inference cheating, is not necessarily a central consideration in smart drug use [16, 17]. Thirdly, the 
failure to find any effect could arise from the fact that those with fixed intelligence beliefs may view using 
smart drugs is futile, given their perceived limited intelligences. Finally, the lack of any relationship between 
implicit intelligence beliefs and smart drugs could also suggest that intelligence beliefs about personal 
attributes do not impact on opinions about exogenous factors i.e. whether you believe you can improve your 
intelligence or not does not impact on whether you believe a drug could bring about the same effect. This has 
interesting implications for education interventions. In addition to there being no impact of intelligence beliefs 
on attitudes, we also found no relationship between morality beliefs and smart drugs. Given the bioethical 
debate sparked by smart drugs, we had hypothesized that morality beliefs would impact on attitudes towards 
these drugs. The lack of effect seen here, may also arise because the self-nature of the beliefs does not directly 
relate to exogenous factors. However, it is also possible that whilst smart drugs are known to create ethical 
debate, this does not necessarily equate to morality. Indeed, whilst ethics and morality are undoubtedly linked, 
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they are arguably separate constructs and one can exist and be measured in the absence of the other [55]. 
Indeed, it has been suggested there are four key distinctions between ethics and morality [56]. Firstly, ethics 
can be viewed as convictions about what is a good or bad life to lead, whilst morality represents the principles 
about how we should treat others. Secondly, ethics is concerned with convictions about character e.g. how we 
should act, what we should like and what we should care about. By contrast morality is about actual voluntary 
actions, normally in the context of a specific event. Thirdly, ethics can be measured on a continuum whereas 
morality is treated as a dichotomous variable, normally either right or wrong. Finally, ethics is self-regarding, 
providing personal ideals about the self, whilst morality is other-regarding giving universal rules as to how 
we should act towards others. Whilst previous research into smart drugs has focussed on ethical considerations 
[12, 16, 17, 32], the current study focussed on morality only and there is some limited evidence to suggest this 
may be less important. For example, it has been found use of smart drugs is self-determined and not influenced 
by others [17], indicating that people are self-focused when they think about the benefits and disadvantages 
of smart drug use, and therefore, this is self- rather than other-referential. Whilst the distinction between ethics 
and morality may explain the lack of findings here, it is also possible that we did not find any significant 
relationships because of a lack of spread in our morality measures. However, our data show that measures of 
morality were normally distributed around a mean of 3.87 with the full range of values represented, indicating 
this is unlikely. Future research should consider directly examining measures of ethics and morality in the 
same cohort. Finally, for the implicit theories for both intelligence and morality, it is possible that they do still 
impact on behaviour but not on attitudes, as discussed above in relation to stress. 
 
Limitations of our study must be acknowledged. Firstly, whilst sufficiently large to power our statistical 
analyses, the representativeness of our sample may be questioned. The study was open to all UK full time 
undergraduate students, although it would seem likely that the majority participating were at the host 
institution. However, we did not collect additional data on discipline or university and therefore cannot be 
sure how representative our sample is for the UK university population as a whole or the population at the 
host university. This means that factors such as competitiveness cannot be extracted from the data. 
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Additionally, within our sample, 17% reported having previously used smart drugs, a prevalence rate higher 
than documented in other UK studies [14, 15]. A significantly higher percentage of males had used smart 
drugs (35%) than had females (10%), which corresponds with some previous research [15]. However, our 
sample was predominantly female (71%), and the under-representation of males (29%) potentially questions 
the robustness of the prevalence rate we observed among male participants. We did not find any impact of age 
on our key outcome measures, although this may be because despite a wide range, the majority fell within 18-
25 years meaning the sample was not very diverse. It is possible that a more diverse sample, for example, 
collected by including postgraduate students, may see subtle effects of age. Larger-scale surveys, conducted 
with support from senior management at multiple institutions, might seek to replicate our findings among a 
more representative sample. Secondly, our study sought to predict attitudes rather than behaviour itself. Whilst 
attitudes are important in determining behaviour, they do not provide the full picture and therefore, factors 
such as stress and intelligence beliefs may better correspond to other predictors of behaviour. Finally, we did 
not attempt to identify causality in our design. The study was cross-sectional, and we cannot be sure of the 
direction of any relationships as discussed above. Nonetheless, our findings suggest that efforts to curb smart 
drug use might fruitfully focus on emphasising evidence of the potential health risks associated with smart 
drug use among non-clinical populations [7, 18], absence of evidence regarding longer-term impact [19], or 
the ethical or moral arguments that proscribe smart drug use.  
Conclusion 
 
Our study has shown that students who tend to have more positive attitudes towards using smart drugs when 
they consider smart drugs harmless, believe they should be freely accessible, and believe they know enough 
about smart drugs to use them safely also hold more positive attitudes, and do not view their use as unfair. 
Stress, and implicit beliefs around the nature of intelligence and morality, had no impact on attitudes. We 
encourage intervention developers who wish to reduce the use of smart drugs, to focus their issues of the 
safety and fairness of smart drugs.  
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Table 1 
Correlates between attitudes towards and use of smart drugs and intelligence and morality beliefs *p<.05 **p<0.001  
 
 Scale 
Range 
Mean SD N 1 2 3 4 5 6 7 8 
1. Attitude 1-5 2.46 1.04 420 -        
2. Study Stress  1-5 2.87 .71 420 .03 -       
3. Intelligence Beliefs 1-6 3.68 .98 420 -.00 -.01 -      
4. Morality Beliefs 1-6 3.87 1.19 419 .02 .04 -.06 -     
5. Awareness and Availability  1-5 2.73 1.04 418 .30** .00 .02 -.02 -    
6. Perceived Harmlessness  1-5 2.16 .95 419 .71** .09* -.03 -.01 .22** -   
7. Perceived Safety Knowledge  1-5 2.25 1.33 420 .52** -.03 -.13* -.05 .45** .46** -  
8. Unfairness  1-5 3.31 1.20 419 -.40** .02 -.06 .10* -.14* -.24** -.24** - 
19 
 
Table 2 
 
Final multiple regression model: predictors of attitude towards smart drugs  
 
Final Model SE B  
Perceived Harmlessness .039 .615 .560** 
Perceived Safety Knowledge .028 .166 .211** 
Unfairness .029 -.184 -.212** 
R2 .589   
Model F 197.50   
**p < 0.001 
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